BioSpace News Archive

ADvantage Therapeutics, Inc. announced the election of James O’Neill — a recognized leader in health, aging, and longevity — to its Board of Directors.

Neurelis, Inc., announced the first two cohorts dosed in the investigational clinical trial of NRL-1049, a Rho kinase (ROCK) inhibitor, a potential treatment for people living with cerebral cavernous malformations (CCM), a disease characterized by abnormally enlarged capillary cavities in the brain and spinal cord.

Today, the U.S. Food and Drug Administration issued draft guidance, Clinical Trial Considerations to Support Accelerated Approval of Oncology Therapeutics, regarding clinical trial design considerations to support accelerated approval applications.

Getinge’s iCast™ covered stent system has received premarket approval from the U.S. Food and Drug Administration (FDA) for the treatment of patients with iliac arterial occlusive disease.

INVO Bioscience, Inc. today announced that it has entered into a securities purchase agreement with a single healthcare focused institutional investor to purchase 3,680,000 shares of common stock (or pre-funded warrants in lieu thereof) in a registered direct offering priced at-the-market under Nasdaq rules.

bioAffinity Technologies , Inc. (NASDAQ: BIAF; BIAFW) today announced it will report financial results for the three months ended December 31, 2022, on Friday, March 31, 2023, after the market close.

Treatments for various forms of breast cancer continue to evolve, with several new breakthroughs being labeled as landmark in nature and giving hope to families dealing with a fateful diagnosis.

HDT Bio Corp. today announced the peer-reviewed publication of preclinical data demonstrating that its self-amplifying replicon mRNA (repRNA) vaccines, delivered via HDT Bio’s proprietary LION nanoparticle formulation, provide robust maternal and neonatal immunogenicity against two pathogens with high mother-to-child transmission risk: HIV-1 and Zika virus (ZIKV).

Alimera Sciences, Inc. (Nasdaq: ALIM) (Alimera) announces today that it will report fourth quarter and full year 2022 financial results on Friday, March 31, 2023, before the market opens.

IntelGenx Technologies Corp. (TSX:IGX) (OTCQB:IGXT) (“IntelGenx”), a leader in pharmaceutical films, today announced that, further to its press release of March 23, 2023, it now plans to release its fourth quarter and full year 2022 financial results after market close on Wednesday, March 29, 2023.